Kevin Shannon
About Kevin Shannon
Kevin Shannon (age 70) is an Independent Director of Morgan Stanley Direct Lending Fund (MSDL), serving since 2019 with his current Class I term expiring at the 2026 annual meeting . He was CFO of Harvard Management Company from 2009–2020, previously CFO/EVP at Moore Capital Management, senior finance roles at Lehman Brothers, and began as an auditor at KPMG; he holds a BS magna cum laude from NYU and an MBA from Fairleigh Dickinson University . He also serves on the boards of the other MS BDCs, has chaired valuation/risk committees in prior roles, and is active in community organizations and industry groups (Managed Funds Association) . The Board has determined he is an Independent Director under NYSE and 1940 Act standards and an “audit committee financial expert” .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Harvard Management Company, Inc. | Chief Financial Officer | Sep 2009–Apr 2020 | Operating Committee (2009–2018), chaired Valuation Committee (Jun 2015–Dec 2017); oversaw Trust & Gifts Group since Dec 2016 |
| Moore Capital Management, LLC | CFO and Executive Vice President | ~15 years (prior to HMC) | Board member, Risk Committee, Valuation Committee; responsible for treasury functions |
| Lehman Brothers | Senior Vice President; CFO of derivatives products subsidiary; Director of Firm Trading Accounting & Controls | Prior to Moore Capital | Finance, controls, derivatives oversight |
| KPMG LLP | Auditor (financial services clients) | Career start | Audit practice |
| Baruch College (Dept. of Accounting) | Adjunct lecturer (part-time) | Two-year tenure | Academic teaching |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Managed Funds Association | Director; Executive Committee Vice Chairman and Treasurer | Two consecutive terms (dates not specified) | Executive Committee leadership |
| Efferent Health, LLC (private) | Advisory Committee member | Current (date not specified) | Advises medical imaging/data management venture |
| Help for Children | Board member | ~20 years; board service ended Dec 31, 2023 | Former Audit and Executive Committees |
| Boston Economics Club | Member | Current (date not specified) | Professional network membership |
| MS BDCs in Fund Complex (T Series, PIF, PIF A, LGAM, SLIF) | Director across MS BDCs | Since formation (various dates) | Oversees 6 portfolios in Fund Complex |
Board Governance
-
Committee assignments and chairs:
- Compensation Committee: Shannon is Chair; members include Binstock, Frank, Metz; all Independent under NYSE and 1940 Act .
- Audit Committee: Member; all Independent under NYSE/Exchange Act; Board determined Shannon is an “audit committee financial expert” .
- Nominating & Corporate Governance Committee: Member; all Independent; Chair is Binstock .
-
Independence and attendance:
- Independent Director status affirmed after review of relationships under 1940 Act; Independent Directors comprise all committees .
- Board met 5 times in 2024; no incumbent Director attended fewer than 75% of Board and relevant committee meetings; 2 Directors attended the 2024 annual meeting .
-
Lead Independent Director and executive sessions:
- Company does not currently have a designated Lead Independent Director; offsets potential conflicts with regular executive sessions of Independent Directors and Independent-only committees .
Committee Meeting Activity
| Committee | FY 2023 Meetings | FY 2024 Meetings |
|---|---|---|
| Audit | 4 | 4 |
| Compensation | 1 | 2 |
| Nominating & Corporate Governance | 2 | 4 |
Fixed Compensation
- Policy changes:
- Pre-IPO (through Jan 26, 2024): Independent Directors received $75,000 annual fee; meeting fees ($2,000 per in-person Board, $1,000 telephonic; $1,000 per in-person committee, $500 telephonic, if not same day); Audit Chair received additional $7,500 .
- Post-IPO (from Jan 26, 2024): Annual fee increased to $125,000; Audit Chair additional $15,000; reasonable out-of-pocket expenses reimbursed .
| Component | Pre-IPO | Post-IPO |
|---|---|---|
| Annual Director Fee (Cash) | $75,000 | $125,000 |
| Audit Committee Chair Fee (Cash) | $7,500 | $15,000 |
| Meeting Fees | Board: $2,000 in-person / $1,000 telephonic; Committee: $1,000 in-person / $500 telephonic (if not same day) | Not specified post-IPO (policy highlights annual fee) |
- Actual compensation paid (Company and Fund Complex totals):
| Metric | 2021 | 2023 | 2024 |
|---|---|---|---|
| Total Compensation from Company (USD) | $83,000 | $75,000 | $122,703 |
| Total Compensation from Fund Complex (USD) | $143,900 | $276,164 | $374,945 |
Note: Fund Complex includes MSDL, T Series, PIF, PIF A, LGAM, SL Investment Corp. and SLIF .
Performance Compensation
| Metric | Status |
|---|---|
| Stock options | No awards granted in FY 2024; Item 402(x) not applicable |
| RSUs/PSUs (Director) | No director equity awards disclosed; Independent Director compensation described as cash fees/retainers |
| Performance metrics tied to director compensation | None disclosed; Compensation Committee will not produce an executive compensation report because executives are not paid directly by the Company |
Other Directorships & Interlocks
| Company/Entity | Role | Interlock/Relationship |
|---|---|---|
| Other MS BDCs (T Series, PIF, PIF A, LGAM, SLIF) | Director | Shared adviser (Morgan Stanley IM) across Fund Complex; Shannon serves on all MS BDC boards since formation |
| Public/registered investment companies outside MS BDCs | None in past five years | As disclosed in director biography table |
| Efferent Health, LLC | Advisory Committee member | Private healthcare startup; advisory capacity |
| Managed Funds Association | Board and Exec Committee roles | Industry association; prior leadership roles |
Expertise & Qualifications
- Audit committee financial expert designation under Item 407 of Regulation S‑K .
- Senior finance leadership across endowment, hedge fund, and sell-side derivatives operations (HMC, Moore Capital, Lehman) .
- Valuation and risk committee experience; treasury and control functions oversight .
- Academic credentials: BS magna cum laude (NYU) and MBA (Fairleigh Dickinson) .
Equity Ownership
- Beneficial ownership and alignment:
- Shares beneficially owned as of the Record Date: 24,080; less than 1% of outstanding (87,920,526 shares) .
- Prior year beneficial holdings: 24,079 (as of 2024 Record Date; 88,894,490 shares outstanding) .
- Earlier holdings: 17,520.858 (as of 2022 Record Date; 57,196,918.324 shares outstanding) .
- Dollar range ownership: “Over $100,000” in Company; “Over $100,000” aggregate in Fund Complex across years .
| Metric | 2022 | 2024 | 2025 |
|---|---|---|---|
| Shares Beneficially Owned | 17,520.858 | 24,079 | 24,080 |
| % of Shares Outstanding | <1% (57.2M SO) | <1% (88.9M SO) | <1% (87.9M SO) |
| Dollar Range – Company | Over $100,000 | Over $100,000 | Over $100,000 |
| Dollar Range – Fund Complex | Over $100,000 | Over $100,000 | Over $100,000 |
- Hedging/pledging:
- Code of Ethics does not expressly prohibit hedging transactions (e.g., collars, swaps, exchange funds) by directors or the Adviser’s personnel .
- Pledging practices not disclosed .
Insider Trades (2025)
| Filing Date | Transaction Date | Type | Shares | Price | Post-Transaction Ownership | SEC Link |
|---|---|---|---|---|---|---|
| 2025-08-18 | 2025-08-14 | Open market purchase | 5,000 | $17.70 | 29,079 | |
| 2025-06-10 | 2025-06-06 | Open market purchase | 5,700 (indirect) | $19.425 | 5,700 | |
| 2025-06-10 | 2025-06-06 | Open market purchase | 2,300 (indirect) | $19.4397 | 2,300 | |
| 2025-06-10 | 2025-06-06 | Open market purchase | 2,000 (indirect) | $19.43 | 2,000 |
Governance Assessment
-
Board effectiveness and independence:
- Shannon’s finance, valuation, and risk credentials strengthen audit oversight; designation as an audit committee financial expert and chairing the Compensation Committee since Sep 2023 indicate active, relevant governance engagement .
- Attendance expectations met; no Director fell below 75%, and committee activity increased in 2024 (notably Nominating & Corporate Governance and Compensation) .
-
Alignment and incentives:
- Compensation for Independent Directors is cash-based; post-IPO retainer increase to $125k with audit chair premium; no equity/option awards disclosed for directors—reduces dilution but can limit alignment versus equity-based plans .
- Shannon holds >$100k in MSDL and made open market purchases in 2025, a positive alignment signal for investors .
-
Conflicts and related-party exposure:
- External management via Morgan Stanley adviser; significant advisory/incentive fees paid (2024 base management fees $25.48M net of waiver; income-based incentive fees $37.43M); quarterly Audit Committee review of related-party transactions mitigates risks .
- MS&Co underwriting IPO fees ($1.24M) and notes placement fees ($210,180) indicate affiliate transactions; board independence and oversight structures are important safeguards .
-
RED FLAGS
- Hedging not explicitly prohibited in Code of Ethics could undermine ownership alignment if used; absence of disclosed stock ownership guidelines for directors is a governance gap .
- No Lead Independent Director while an Interested Director chairs the Board increases perceived conflict risk; mitigations include independent-only committees and executive sessions but investors may prefer a lead independent role .
Overall, Shannon’s deep finance background, audit/valuation experience, and recent open market purchases support investor confidence, while structural conflicts inherent to externally managed BDCs and permissive hedging policy warrant close monitoring of committee governance and related-party oversight .